GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (OSTO:XBRANE) » Definitions » Cash Receipts from Securities Related Activities

Xbrane Biopharma AB (OSTO:XBRANE) Cash Receipts from Securities Related Activities


View and export this data going back to 2016. Start your Free Trial

What is Xbrane Biopharma AB Cash Receipts from Securities Related Activities?

Cash Receipts from Securities Related Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Xbrane Biopharma AB (OSTO:XBRANE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (OSTO:XBRANE) » Definitions » Cash Receipts from Securities Related Activities
Traded in Other Exchanges
Address
Retzius vag 8, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.